SlideShare a Scribd company logo
Treatment and
Recovery in America
        April 10-12, 2012
 Walt Disney World Swan Resort
Accepted Learning Objectives:
1. Define when and how medication-assisted
treatment methodologies for successful
recovery of opioid addiction should be used.
2. Explain how to improve access and quality of
care through strategic planning and
community-wide coordination with local and
state agencies.
3. Describe behavioral health issues faced by
individuals within the corrections system and
devise strategies to adequately address these
clinical needs after incarceration.
Disclosure Statement
•  All presenters for this session, Dr. Elinore
   McCance-Katz and Gregory C.
   Warren, have disclosed no relevant,
   real or apparent personal or
   professional financial relationships.
Baltimore Substance
Abuse Systems, Inc.

 Nuts and Bolts of
   Medication
Assisted Treatment
   and System
  Coordination
Baltimore Substance Abuse
        Systems, Inc.
BSAS is a quasi-public agency incorporated in
1990.

In 1995, BSAS became responsible for the
management of the publicly-funded substance
abuse treatment and prevention service system.

The Chair of the 27-member Board is the
Commissioner of Health.
Baltimore City’s Challenge
•  Heroin addiction remains high
  –  Treatment capacity falls short of demand despite
     expansion in treatment system
  –  Estimated 30,000 individuals with opioid
     dependence
  –  ~4,000 methadone treatment slots
  –  Over 8,000 treatment admissions for opioids in FY
     2008

•  Consequences from heroin addiction are severe
  –  Crime
  –  Family and community disruption
  –  Medical complications
     •  1 in 48 Baltimore City residents are living
        with HIV and/or AIDS
,     .

  57%
arrested       71% Unemployed
 in the       50% < $10,000 per yr.
 past 2
 years
                             Characteristics of Clients in
   60%                       Baltimore City Programs
                  13%
   male
                Homeless     FY 2010

   77%
   use                                     Treatment
 tobacco        45%
                                            Episodes
                less than a 12th
                                           n = 21,000
                grade education
   70%
 between      83% Black,
30-50 years   16% White
  of age      Less than 1% Hispanic
Neighborhood Factors
•  78% felt drugs was a major problem
•  31% felt neighborhood was safe to live
•  26% felt neighborhood was a good
   place to find a job
•  59% felt living in the neighborhood
   made it hard to stay out of jail
BSAS Vision and Mission
                         VISION
We envision Baltimore as a city with healthy people, thriving
             families and safe communities.

                          Mission
 Baltimore Substance Abuse Systems seeks to ensure that
Baltimore residents receive high quality and comprehensive
 services proved to prevent and reduce substance abuse.
                HOW WE WILL ACHIEVE THIS
We do this by planning, advocating for and helping to
create coordinated networks of community-based and
recovery focused services that build on the strengths and
resilience of individuals, families, and communities.
Concerns for the Future
•  Do our citizens have access to care?

•  Do our citizens receive quality care?

•  Individualized, continuous, coordinated care is better than
   disjointed, acute care which ignores the importance of the
   family and community

•  Cultural and clinical diversity of services are better than
   “cookie cutter treatment”
Key Philosophical
         Understandings
•  Pain and suffering are powerful
   motivators for change
•  We need to be where people have
   their motivational moments
•  Medication assisted treatment
   provides the time for counseling to
   work
Recovery Oriented
     Systems of Care (ROSC)
   Networks of formal and informal services
  developed and mobilized to sustain long-
  term recovery for individuals and families
  impacted by substance abuse.

“ The act of asking what the patient wants
   instead of what will be done to the patient.”
Buprenorphine:        14
Methadone:       13
What is different about
  buprenorphine?
Buprenorphine Formulations
Buprenex (for pain only)



Subutex (for opioid addiction only)



Suboxone (for opioid addiction only, with naloxone)
How long do people need to stay
      on buprenorphine?
•  Individualized
•  Studies demonstrate that staying on
   medication in combination with
   counseling results in much better
   outcomes than detox
•  50% relapse rate within a year among
   patients who came off
Outcomes for Treatment As Usual
•  Of 3,753 admissions to Level I treatment in
   FY08, 51% retained for 90 days or more

•  Of 11,013 treatment discharges in FY08, only
   Prince George’s county had smaller change
   in substance use

•  Relapse rates high
  –  In methadone studies, 50-80% relapse within one
     year after detoxification
  –  91% of patients receiving buprenorphine for 4
     months had relapsed to prescription
     opioids within 2 months of taper*
Business Case for BBI in 2006
•  Baltimore needs more effective treatment
   for opioid dependence

•  Review of literature and studies by UMBC
    –  Medical costs are increased for patients
       with drug abuse
  –  Opioid addicts on methadone consume far
     fewer Medicaid resources than addicts who go
     untreated
  –  Buprenorphine is economically viable alternative
     in city with limited methadone treatment
     capacity

                                                    19
Dept of Public Safety and
      Correctional Services
•  Maryland manages the Detention
   Center
  –  4,000 inmates
     •  Men have a LOS of 28 days
     •  Women have a LOS of 60 days
•  Division of Correction
  –  22,000 inmate population
     •  12,000 released annually
     •  9,000 are Baltimore City residents
        –  Over 70% have a diagnosis of Substance Abuse
OTP Interventions

•  Maintain arrested OTP clients during Pre-Trial Status and
   reconnect them to their OTP at release

•  Detox heroin-addicted inmates with non-opioids or on
   methadone

•  Pregnancy protocol


•  Buprenorphine conversion
Criminal History of Prison-based OTP Patients 1

                                      Mean
       Age first crime                 13.8
       Age first arrest                16.5
       Age first incarceration         20.6
       Lifetime incarcerations           9.1
       Past 30 days crime              25.5
       Past 30 days crime-profit       24.8
       Criminal Income ($/past        8,057
       30 days)
1 Kinlock,   Schwartz Gordon (2005)
Treating Prisoners with Heroin
           Addiction Histories

  Most detainees with histories of heroin addiction do
   not receive drug abuse treatment while
   incarcerated
  Such inmates typically become re-addicted within
   one month of release
  Re-addiction is accompanied by the following:
        Increased criminal activity
        Unemployment
        High risk of HIV infection
        Greater risk of overdose death
        Incarceration
Offenders have more serious Substance
                   Use & Other Disorders




       •  Offenders Have Higher Rates of Psycho-Social
          Dysfunctional Than the General Population
                –  Substance Use Disorders
                –  Mental Health and Somatic Health Disorders
                –  Educational Deficiencies
       •  CJ Populations: 4 Times Greater SA Disorders
NSDUH	
  2007	
  
BBI Results
       3,209 patients                • Currently, 357
          treated
                                     patients receiving
                                     full BBI services in
  2,094 (65%) obtained or
  had medical assistance
                                     treatment
                                     program
1,645 (79%)       449 (21%)
    PAC         Health Choice        • Approximately
                                     6% drop-out from
                      796 (38%)      continuing care
                    transferred to
                   continuing care
bSAS and B-MAT: Results
•  After controlling for baseline group differences, the B-MAT group
   had less:
       –  Inpatient hospital admissions
       –  Inpatient days in hospital
       –  Outpatient hospital visits
       –  Emergency room visits
       –  Physician visits
•  However, the only statistically significant differences compared to
   M-MAT and Abstinence-based treatment was for physician visits
•  The M-MAT group has more health problems while the B-MAT and
   Abstinence groups have similar profiles


  26
Factors to Improve Networkness?
Integration or Boundaryless Processes of SA & CJ
                     Agencies
         Most Typical Activities:
         •  Share Information with                                                    Average Number of
            agencies                                                                   Activities Integrated:
         •  Develop Client Eligibility                                                    Drug Court=6.1
            Across Agencies                                                               Probation/Parole=4.5
         •  Written Program                                                               Prison=3.2
            Programs                                                                      Jails=3.7
         •  Joint Staffing of Program                                                 Interagency integration is
         •  Modified Program to Meet                                                   associated with more use
            Correctional and SA                                                        of EBPs, more holistic
            Agencies                                                                   services, and improved
                                                                                       outcomes
         •  Written MOU between
            agency




Fletcher,	
  et	
  al,	
  in	
  press	
  ;	
  Taxman	
  &	
  Perdoni,	
  2007	
  
Project ACCESS

•    Accountability
•    Communication
•    Collaboration
•    Efficiency
•    Security of Information
•    Service focus
BSAS ACCESS

    Supports BSAS, Vision, Mission and Goals

  EHRc Information Sharing supports continuity of care.

 EHRc Information Sharing furthers the goals of a ROSC
approach.

 EHRc Information Sharing frees up funding and staff so that it
can be applied to improved Quality of Care.

• EHRc Information Sharing expands, consolidates and improves the
quality of Public Health Data Repository.

• EHRc Information Sharing provides better quality and more complete
data for evaluation and outcome reporting.
BSAS ACCESS
  Health Information Strategic
            Planning
  New ways to collect, share and use data to serve
   client.
  Interoperable systems and smooth information flow.
  “Wherever you go, there you are”
•  Better Quality data – reliable, consistent, complete.
•  New partnerships and collaborations in evaluating and
   applying meaningful data.
•  Confidentiality and Consent
What providers tell us they want from their
                    Information Systems
     (From focus group discussions, interviews and in depth needs analyses)

  A fully functional, modern and meaningful use certified
   EHR
  Consolidation of Information Systems and elimination of
   redundant applications
  Access to additional client data and interoperability with
   other client data systems

•    Pricing discounts and additional leverage associated with
     forming an EHR (HIT) consortium
•    Business practice and clinical practice management
     Information Systems improvements
•    HIT advisement – How to get CMS incentive payments and how
     to avoid penalties
Draft - ACCESS Advisory Board
•    Behavioral Health Treatment Providers (2)
•    Consumers (2)
•    BSAS CEO
•    BSAS CIO
•    DPSCS CIO
•    Baltimore City CIO
•    DHMH CIO
•    BSAS Epidemiologist
•    University of Maryland Law Clinic
•    Health Care Access Maryland
Treatment Outcomes for the
         Criminal Justice Population
                            Criminal Justice Populations

         Drug Treatment Court                       Other Criminal Justice
                N = 1,353                                  N = 2,745



           Completion: 1,068                          Completion: 1,687
           Incarceration: 21                          Incarceration: 71
            Terminated: 264                            Terminated: 987


      Treatment Outcomes                                Drug Court   Non-Drug Court
Drug use during treatment                     13%      38%
Substance use at discharge                    10%          25%
90 day retention in outpatient treatment (Level I)     63%     57%
Completion of outpatient treatment (Level I)           52%     34%
Continuity of care from ICF (Level III.7) to another LOC 73%       35%
% change in employment from admission to discharge 183%                52%
Treatment Outcomes for the
         Criminal Justice Population
                            Criminal Justice Populations

         Drug Treatment Court                       Other Criminal Justice
                N = 1,353                                  N = 2,745



           Completion: 1,068                          Completion: 1,687
           Incarceration: 21                          Incarceration: 71
            Terminated: 264                            Terminated: 987


      Treatment Outcomes                                Drug Court   Non-Drug Court
Drug use during treatment                     13%      38%
Substance use at discharge                    10%          25%
90 day retention in outpatient treatment (Level I)     63%     57%
Completion of outpatient treatment (Level I)           52%     34%
Continuity of care from ICF (Level III.7) to another LOC 73%       35%
% change in employment from admission to discharge 183%                52%
Access:
         The Patient-Centered, Clinical Case Management Approach
        A Recovery Oriented System of Care Not Constrained by Walls




           Offender                                    Patient
             NEEDS                                       NEEDS

 • Custody                                    • Substance Abuse treatment
 • Somatic Care                               • Mental Health treatment
 • Substance Abuse Treatment                  • Somatic Care
 • Mental Health Treatment                    • Housing
 • Case Management                            • Entitlement Benefits
                                              • Family Support Services
                                              • Faith-Based Services


DPDS          DOC              DPP      Health Dept./Community Services
Shared Critical Understanding
•  Correctional Services is an expectation
   of the public
•  DPSCS is a part of Maryland’s public
   health system
•  Our success is measured long after our
   offenders/patients leave
DPSCS and BSAS have a
      Shared Challenge
Information must follow the offender/
patient and not reside and remain at
the institution for it to do the greatest
                 good.

  The Patient-Centered Approach
The Benefits of a DPSCS/BSAS
         Partnership
•  BSAS will champion critical value added
   linkages which will improve offender’s health
   outcomes
•  DPSCS/BSAS health information exchange
   becomes a higher priority to CRISP
•  Direct benefit to 9,000 returning Baltimore
   City offenders annually
BSAS ACCESS

                    The Value Proposition
 Full-featured, meaningful use certified EHR for providers and
partners.
 Consolidation of multiple provider applications on a single
operating platform. (Replace UP and eliminate SMART data entry.)
 Information sharing between community resources and DPSCS.
 Steep discounts for high quality solution to providers and
partners.

•  More efficient and cost effective clinical and practice management for
providers and partners
• BSAS consultation and assistance in securing Medicaid incentive
payments.
• Information sharing between BSAS provider network, mental health,
primary care providers, and other community resources.
• Primary source, comprehensive public health data repository.
• Comprehensive statistical evaluation
and outcome reporting
BSAS- ACCESS

                        Design & Implementation




•    Secure, segregated installations on a common operating platform
•    Custom module selection and configuration.
•    Economies of scale and cost reductions
•    Data sharing and information exchange
•    Aggregate public health data
BSAS ACCESS
                       Patient Management Work Flow



                                Intake Administration
Client Referral / Client      Scheduling and Releases
        Walk-in                         AND                   Consent
                                 DATA FROM OTHER
                               CONSORTIUM MEMBERS




                              Methadone (Other Meds)        Clinical Case
     EPrescription                Management /             Management /
                                    Dispensing             Documentation




  Billing /Accounts
                                Standard Practice       Compliance Reporting
Receivable/Financial
   Management                 Management Reporting       City, State, Federal
BSAS Health Information Exchange


                                        DPSCS
                                        OCMS                 BSAS
                BSAS                                       Methadon
             Residential                                       e
                                                           Programs



                                                                    BSAS
  BHCA
                                                                  Outpatien
Entitlemen                         BSAS ACCESS                        t
      t
                                                                  Programs
 Benefits


                                                                 FQHC
        DHMH                                                      GE
        SMART                                                   Centricity
                             Health              Health
                            Providers           Departme
                           thru CRISP              nt

More Related Content

What's hot

Brightpoint Health Leaders Address US Conference on AIDS on the need for Inte...
Brightpoint Health Leaders Address US Conference on AIDS on the need for Inte...Brightpoint Health Leaders Address US Conference on AIDS on the need for Inte...
Brightpoint Health Leaders Address US Conference on AIDS on the need for Inte...
lsolomon212
 
State of Wellness - CDC
State of Wellness - CDCState of Wellness - CDC
State of Wellness - CDC
HPCareer.Net / State of Wellness Inc.
 
4.gpt ppt dr alexandervfor cmap_rtg_final
4.gpt ppt dr alexandervfor cmap_rtg_final4.gpt ppt dr alexandervfor cmap_rtg_final
4.gpt ppt dr alexandervfor cmap_rtg_final
Samantha Haas
 
Guidance for commissioners of rehabilitation services
Guidance for commissioners of rehabilitation servicesGuidance for commissioners of rehabilitation services
Guidance for commissioners of rehabilitation services
JCP MH
 
Web only rx16 treat-wed_1115_1_hudson_2bada
Web only rx16 treat-wed_1115_1_hudson_2badaWeb only rx16 treat-wed_1115_1_hudson_2bada
Web only rx16 treat-wed_1115_1_hudson_2bada
OPUNITE
 
Becoming a leader_final
Becoming a leader_finalBecoming a leader_final
Becoming a leader_final
OPUNITE
 
The Role of CHAs
The Role of CHAsThe Role of CHAs
The Role of CHAs
ConnectProjectTZ
 
Reducing hiv sti risk and improving treatment for men who have sex with men i...
Reducing hiv sti risk and improving treatment for men who have sex with men i...Reducing hiv sti risk and improving treatment for men who have sex with men i...
Reducing hiv sti risk and improving treatment for men who have sex with men i...
National Organization of Peer Educators (NOPE Kenya)
 
Recognising_LGB_Sexual_Identities_in_Health_Services
Recognising_LGB_Sexual_Identities_in_Health_ServicesRecognising_LGB_Sexual_Identities_in_Health_Services
Recognising_LGB_Sexual_Identities_in_Health_Services
Mary Manandhar
 
Final project - Erin Gates
Final project - Erin GatesFinal project - Erin Gates
Final project - Erin Gates
ratpuppycat7
 
Tobacco Dependence Treatment Training -- J. Taylor Hays, M.D.
Tobacco Dependence Treatment Training -- J. Taylor Hays, M.D.Tobacco Dependence Treatment Training -- J. Taylor Hays, M.D.
Tobacco Dependence Treatment Training -- J. Taylor Hays, M.D.
Global Bridges
 
COUPLES BEHAVIORAL THERAPY- FINAL
COUPLES BEHAVIORAL THERAPY- FINALCOUPLES BEHAVIORAL THERAPY- FINAL
COUPLES BEHAVIORAL THERAPY- FINAL
Stephanie Brinkerhoff, JD, LCSW
 
Successful Social and Financial Outcomes for Complicated Patients
Successful Social and Financial Outcomes for Complicated PatientsSuccessful Social and Financial Outcomes for Complicated Patients
Successful Social and Financial Outcomes for Complicated Patients
Michigan Primary Care Association
 
AIDSTAR-One Case Study: Prioritizing HIV in Mental Health Services Delivered ...
AIDSTAR-One Case Study: Prioritizing HIV in Mental Health Services Delivered ...AIDSTAR-One Case Study: Prioritizing HIV in Mental Health Services Delivered ...
AIDSTAR-One Case Study: Prioritizing HIV in Mental Health Services Delivered ...
AIDSTAROne
 
Birmingham Total Place Summit Master Class
Birmingham Total Place Summit Master ClassBirmingham Total Place Summit Master Class
Birmingham Total Place Summit Master Class
LeadershipCentre
 
What your organisation needs to know about personal health budgets, communica...
What your organisation needs to know about personal health budgets, communica...What your organisation needs to know about personal health budgets, communica...
What your organisation needs to know about personal health budgets, communica...
CharityComms
 
Aidstar-One Case Study Georiga Harm Reduction Network_tagged
Aidstar-One Case Study Georiga Harm Reduction Network_taggedAidstar-One Case Study Georiga Harm Reduction Network_tagged
Aidstar-One Case Study Georiga Harm Reduction Network_tagged
AIDSTAROne
 
Behavioral Health Integration in Primary Care 1
Behavioral Health Integration in Primary Care 1Behavioral Health Integration in Primary Care 1
Behavioral Health Integration in Primary Care 1
MPCA
 
Dr Nick Harding - Sandwell and West Birmingham Clinical Commissioning Group's...
Dr Nick Harding - Sandwell and West Birmingham Clinical Commissioning Group's...Dr Nick Harding - Sandwell and West Birmingham Clinical Commissioning Group's...
Dr Nick Harding - Sandwell and West Birmingham Clinical Commissioning Group's...
podnosh
 
BPS SIGOPAC Bristol October 2016 - Dr Sue Smith & Dr Anna Janssen
BPS SIGOPAC Bristol October 2016 - Dr Sue Smith & Dr Anna JanssenBPS SIGOPAC Bristol October 2016 - Dr Sue Smith & Dr Anna Janssen
BPS SIGOPAC Bristol October 2016 - Dr Sue Smith & Dr Anna Janssen
Alex King
 

What's hot (20)

Brightpoint Health Leaders Address US Conference on AIDS on the need for Inte...
Brightpoint Health Leaders Address US Conference on AIDS on the need for Inte...Brightpoint Health Leaders Address US Conference on AIDS on the need for Inte...
Brightpoint Health Leaders Address US Conference on AIDS on the need for Inte...
 
State of Wellness - CDC
State of Wellness - CDCState of Wellness - CDC
State of Wellness - CDC
 
4.gpt ppt dr alexandervfor cmap_rtg_final
4.gpt ppt dr alexandervfor cmap_rtg_final4.gpt ppt dr alexandervfor cmap_rtg_final
4.gpt ppt dr alexandervfor cmap_rtg_final
 
Guidance for commissioners of rehabilitation services
Guidance for commissioners of rehabilitation servicesGuidance for commissioners of rehabilitation services
Guidance for commissioners of rehabilitation services
 
Web only rx16 treat-wed_1115_1_hudson_2bada
Web only rx16 treat-wed_1115_1_hudson_2badaWeb only rx16 treat-wed_1115_1_hudson_2bada
Web only rx16 treat-wed_1115_1_hudson_2bada
 
Becoming a leader_final
Becoming a leader_finalBecoming a leader_final
Becoming a leader_final
 
The Role of CHAs
The Role of CHAsThe Role of CHAs
The Role of CHAs
 
Reducing hiv sti risk and improving treatment for men who have sex with men i...
Reducing hiv sti risk and improving treatment for men who have sex with men i...Reducing hiv sti risk and improving treatment for men who have sex with men i...
Reducing hiv sti risk and improving treatment for men who have sex with men i...
 
Recognising_LGB_Sexual_Identities_in_Health_Services
Recognising_LGB_Sexual_Identities_in_Health_ServicesRecognising_LGB_Sexual_Identities_in_Health_Services
Recognising_LGB_Sexual_Identities_in_Health_Services
 
Final project - Erin Gates
Final project - Erin GatesFinal project - Erin Gates
Final project - Erin Gates
 
Tobacco Dependence Treatment Training -- J. Taylor Hays, M.D.
Tobacco Dependence Treatment Training -- J. Taylor Hays, M.D.Tobacco Dependence Treatment Training -- J. Taylor Hays, M.D.
Tobacco Dependence Treatment Training -- J. Taylor Hays, M.D.
 
COUPLES BEHAVIORAL THERAPY- FINAL
COUPLES BEHAVIORAL THERAPY- FINALCOUPLES BEHAVIORAL THERAPY- FINAL
COUPLES BEHAVIORAL THERAPY- FINAL
 
Successful Social and Financial Outcomes for Complicated Patients
Successful Social and Financial Outcomes for Complicated PatientsSuccessful Social and Financial Outcomes for Complicated Patients
Successful Social and Financial Outcomes for Complicated Patients
 
AIDSTAR-One Case Study: Prioritizing HIV in Mental Health Services Delivered ...
AIDSTAR-One Case Study: Prioritizing HIV in Mental Health Services Delivered ...AIDSTAR-One Case Study: Prioritizing HIV in Mental Health Services Delivered ...
AIDSTAR-One Case Study: Prioritizing HIV in Mental Health Services Delivered ...
 
Birmingham Total Place Summit Master Class
Birmingham Total Place Summit Master ClassBirmingham Total Place Summit Master Class
Birmingham Total Place Summit Master Class
 
What your organisation needs to know about personal health budgets, communica...
What your organisation needs to know about personal health budgets, communica...What your organisation needs to know about personal health budgets, communica...
What your organisation needs to know about personal health budgets, communica...
 
Aidstar-One Case Study Georiga Harm Reduction Network_tagged
Aidstar-One Case Study Georiga Harm Reduction Network_taggedAidstar-One Case Study Georiga Harm Reduction Network_tagged
Aidstar-One Case Study Georiga Harm Reduction Network_tagged
 
Behavioral Health Integration in Primary Care 1
Behavioral Health Integration in Primary Care 1Behavioral Health Integration in Primary Care 1
Behavioral Health Integration in Primary Care 1
 
Dr Nick Harding - Sandwell and West Birmingham Clinical Commissioning Group's...
Dr Nick Harding - Sandwell and West Birmingham Clinical Commissioning Group's...Dr Nick Harding - Sandwell and West Birmingham Clinical Commissioning Group's...
Dr Nick Harding - Sandwell and West Birmingham Clinical Commissioning Group's...
 
BPS SIGOPAC Bristol October 2016 - Dr Sue Smith & Dr Anna Janssen
BPS SIGOPAC Bristol October 2016 - Dr Sue Smith & Dr Anna JanssenBPS SIGOPAC Bristol October 2016 - Dr Sue Smith & Dr Anna Janssen
BPS SIGOPAC Bristol October 2016 - Dr Sue Smith & Dr Anna Janssen
 

Viewers also liked

Vernon Stejskal
Vernon StejskalVernon Stejskal
Vernon Stejskal
OPUNITE
 
Dennis Jay
Dennis JayDennis Jay
Dennis Jay
OPUNITE
 
Michael Gavin
Michael GavinMichael Gavin
Michael Gavin
OPUNITE
 
Peggy Quigg
Peggy QuiggPeggy Quigg
Peggy Quigg
OPUNITE
 
Judy Cushing
Judy CushingJudy Cushing
Judy Cushing
OPUNITE
 
Bruce DiVincenzo
Bruce DiVincenzoBruce DiVincenzo
Bruce DiVincenzo
OPUNITE
 
Elinore McCance-Katz
Elinore McCance-KatzElinore McCance-Katz
Elinore McCance-Katz
OPUNITE
 
Henry Spiller edited
Henry Spiller editedHenry Spiller edited
Henry Spiller edited
OPUNITE
 
Dr. Ileana Arias
Dr. Ileana AriasDr. Ileana Arias
Dr. Ileana Arias
OPUNITE
 
Nora Volkow final edits
Nora Volkow final editsNora Volkow final edits
Nora Volkow final edits
OPUNITE
 

Viewers also liked (10)

Vernon Stejskal
Vernon StejskalVernon Stejskal
Vernon Stejskal
 
Dennis Jay
Dennis JayDennis Jay
Dennis Jay
 
Michael Gavin
Michael GavinMichael Gavin
Michael Gavin
 
Peggy Quigg
Peggy QuiggPeggy Quigg
Peggy Quigg
 
Judy Cushing
Judy CushingJudy Cushing
Judy Cushing
 
Bruce DiVincenzo
Bruce DiVincenzoBruce DiVincenzo
Bruce DiVincenzo
 
Elinore McCance-Katz
Elinore McCance-KatzElinore McCance-Katz
Elinore McCance-Katz
 
Henry Spiller edited
Henry Spiller editedHenry Spiller edited
Henry Spiller edited
 
Dr. Ileana Arias
Dr. Ileana AriasDr. Ileana Arias
Dr. Ileana Arias
 
Nora Volkow final edits
Nora Volkow final editsNora Volkow final edits
Nora Volkow final edits
 

Similar to Greg Warren

Office-Based Opioid Treatment: What You Need to Know: Trends in Behavioral He...
Office-Based Opioid Treatment: What You Need to Know: Trends in Behavioral He...Office-Based Opioid Treatment: What You Need to Know: Trends in Behavioral He...
Office-Based Opioid Treatment: What You Need to Know: Trends in Behavioral He...
Epstein Becker Green
 
Roundtable on Critical Care 2013 Summit
Roundtable on Critical Care 2013 Summit Roundtable on Critical Care 2013 Summit
Roundtable on Critical Care 2013 Summit
Jon Broyles
 
National SBIRT ATTC 4 Hour Curriculum
National SBIRT ATTC 4 Hour CurriculumNational SBIRT ATTC 4 Hour Curriculum
National SBIRT ATTC 4 Hour Curriculum
Crystal Downey, APTD
 
Tom kimball power point presentation iCAAD Stockholm
Tom kimball power point presentation iCAAD StockholmTom kimball power point presentation iCAAD Stockholm
Tom kimball power point presentation iCAAD Stockholm
iCAADEvents
 
Lancaster General Ppt Final
Lancaster General Ppt FinalLancaster General Ppt Final
Lancaster General Ppt Final
Steven Peskin
 
Georgia BASICS : Evaluation Results from Five Years of Intervention for Risky...
Georgia BASICS : Evaluation Results from Five Years of Intervention for Risky...Georgia BASICS : Evaluation Results from Five Years of Intervention for Risky...
Georgia BASICS : Evaluation Results from Five Years of Intervention for Risky...
Georgia State School of Public Health
 
Rx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleRx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earle
OPUNITE
 
Harm Reduction february 2013 Nursing Education Saskatchewan
Harm Reduction february 2013 Nursing Education SaskatchewanHarm Reduction february 2013 Nursing Education Saskatchewan
Harm Reduction february 2013 Nursing Education Saskatchewan
griehl
 
Harm reduction in Zambia
Harm reduction in ZambiaHarm reduction in Zambia
Harm reduction in Zambia
Ravi Paul
 
Rx16 vs claad_tues_800_group
Rx16 vs claad_tues_800_groupRx16 vs claad_tues_800_group
Rx16 vs claad_tues_800_group
OPUNITE
 
C-TAC 2015 National Summit on Advanced Illness Care - Master Slide Deck
C-TAC 2015 National Summit on Advanced Illness Care - Master Slide DeckC-TAC 2015 National Summit on Advanced Illness Care - Master Slide Deck
C-TAC 2015 National Summit on Advanced Illness Care - Master Slide Deck
zbarehmi
 
Karen Biggs - Phoenix Futures
Karen Biggs - Phoenix FuturesKaren Biggs - Phoenix Futures
Karen Biggs - Phoenix Futures
recoveryfestival
 
System Innovation in California: The Impact of MHSA
System Innovation in California: The Impact of MHSASystem Innovation in California: The Impact of MHSA
System Innovation in California: The Impact of MHSA
commteam
 
Human Genomics and Public Health in a Global World: Challenges for Low & Midd...
Human Genomics and Public Health in a Global World: Challenges for Low & Midd...Human Genomics and Public Health in a Global World: Challenges for Low & Midd...
Human Genomics and Public Health in a Global World: Challenges for Low & Midd...
Human Variome Project
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_final
OPUNITE
 
Diversion First Stakeholders Meeting: May 16, 2019
Diversion First Stakeholders Meeting: May 16, 2019Diversion First Stakeholders Meeting: May 16, 2019
Diversion First Stakeholders Meeting: May 16, 2019
Fairfax County
 
Assisted Outpatient Treatment (AOT) for CIT officers
Assisted Outpatient Treatment (AOT) for CIT officersAssisted Outpatient Treatment (AOT) for CIT officers
Assisted Outpatient Treatment (AOT) for CIT officers
ADAMH Board of Franklin County
 
Epic audit presentation
Epic audit presentationEpic audit presentation
Epic audit presentation
logyonetimi
 
Update on NC Pharmacy 2011
Update on NC Pharmacy 2011Update on NC Pharmacy 2011
Update on NC Pharmacy 2011
UNC Eshelman School of Pharmacy
 
Sian Davies & Suzanne Robinson: Functions and mechanisms of priority setting
Sian Davies & Suzanne Robinson: Functions and mechanisms of priority settingSian Davies & Suzanne Robinson: Functions and mechanisms of priority setting
Sian Davies & Suzanne Robinson: Functions and mechanisms of priority setting
Nuffield Trust
 

Similar to Greg Warren (20)

Office-Based Opioid Treatment: What You Need to Know: Trends in Behavioral He...
Office-Based Opioid Treatment: What You Need to Know: Trends in Behavioral He...Office-Based Opioid Treatment: What You Need to Know: Trends in Behavioral He...
Office-Based Opioid Treatment: What You Need to Know: Trends in Behavioral He...
 
Roundtable on Critical Care 2013 Summit
Roundtable on Critical Care 2013 Summit Roundtable on Critical Care 2013 Summit
Roundtable on Critical Care 2013 Summit
 
National SBIRT ATTC 4 Hour Curriculum
National SBIRT ATTC 4 Hour CurriculumNational SBIRT ATTC 4 Hour Curriculum
National SBIRT ATTC 4 Hour Curriculum
 
Tom kimball power point presentation iCAAD Stockholm
Tom kimball power point presentation iCAAD StockholmTom kimball power point presentation iCAAD Stockholm
Tom kimball power point presentation iCAAD Stockholm
 
Lancaster General Ppt Final
Lancaster General Ppt FinalLancaster General Ppt Final
Lancaster General Ppt Final
 
Georgia BASICS : Evaluation Results from Five Years of Intervention for Risky...
Georgia BASICS : Evaluation Results from Five Years of Intervention for Risky...Georgia BASICS : Evaluation Results from Five Years of Intervention for Risky...
Georgia BASICS : Evaluation Results from Five Years of Intervention for Risky...
 
Rx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleRx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earle
 
Harm Reduction february 2013 Nursing Education Saskatchewan
Harm Reduction february 2013 Nursing Education SaskatchewanHarm Reduction february 2013 Nursing Education Saskatchewan
Harm Reduction february 2013 Nursing Education Saskatchewan
 
Harm reduction in Zambia
Harm reduction in ZambiaHarm reduction in Zambia
Harm reduction in Zambia
 
Rx16 vs claad_tues_800_group
Rx16 vs claad_tues_800_groupRx16 vs claad_tues_800_group
Rx16 vs claad_tues_800_group
 
C-TAC 2015 National Summit on Advanced Illness Care - Master Slide Deck
C-TAC 2015 National Summit on Advanced Illness Care - Master Slide DeckC-TAC 2015 National Summit on Advanced Illness Care - Master Slide Deck
C-TAC 2015 National Summit on Advanced Illness Care - Master Slide Deck
 
Karen Biggs - Phoenix Futures
Karen Biggs - Phoenix FuturesKaren Biggs - Phoenix Futures
Karen Biggs - Phoenix Futures
 
System Innovation in California: The Impact of MHSA
System Innovation in California: The Impact of MHSASystem Innovation in California: The Impact of MHSA
System Innovation in California: The Impact of MHSA
 
Human Genomics and Public Health in a Global World: Challenges for Low & Midd...
Human Genomics and Public Health in a Global World: Challenges for Low & Midd...Human Genomics and Public Health in a Global World: Challenges for Low & Midd...
Human Genomics and Public Health in a Global World: Challenges for Low & Midd...
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_final
 
Diversion First Stakeholders Meeting: May 16, 2019
Diversion First Stakeholders Meeting: May 16, 2019Diversion First Stakeholders Meeting: May 16, 2019
Diversion First Stakeholders Meeting: May 16, 2019
 
Assisted Outpatient Treatment (AOT) for CIT officers
Assisted Outpatient Treatment (AOT) for CIT officersAssisted Outpatient Treatment (AOT) for CIT officers
Assisted Outpatient Treatment (AOT) for CIT officers
 
Epic audit presentation
Epic audit presentationEpic audit presentation
Epic audit presentation
 
Update on NC Pharmacy 2011
Update on NC Pharmacy 2011Update on NC Pharmacy 2011
Update on NC Pharmacy 2011
 
Sian Davies & Suzanne Robinson: Functions and mechanisms of priority setting
Sian Davies & Suzanne Robinson: Functions and mechanisms of priority settingSian Davies & Suzanne Robinson: Functions and mechanisms of priority setting
Sian Davies & Suzanne Robinson: Functions and mechanisms of priority setting
 

More from OPUNITE

Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynote
OPUNITE
 
Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynote
OPUNITE
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynote
OPUNITE
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
OPUNITE
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
OPUNITE
 
Rx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyRx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copy
OPUNITE
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelli
OPUNITE
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
OPUNITE
 
Rx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenRx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsen
OPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
OPUNITE
 
Rx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesRx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategies
OPUNITE
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
OPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
OPUNITE
 
Rx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceRx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2price
OPUNITE
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblatt
OPUNITE
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
OPUNITE
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_miller
OPUNITE
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_group
OPUNITE
 
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldRx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
OPUNITE
 
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachioWeb only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
OPUNITE
 

More from OPUNITE (20)

Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynote
 
Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynote
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynote
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
 
Rx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyRx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copy
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelli
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
 
Rx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenRx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsen
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Rx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesRx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategies
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Rx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceRx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2price
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblatt
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_miller
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_group
 
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldRx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
 
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachioWeb only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
 

Recently uploaded

MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHYMERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
DRPREETHIJAMESP
 
How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.
Gokuldas Hospital
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
chiranthgowda16
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
Earlene McNair
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
NX Healthcare
 
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
ZayedKhan38
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
AyeshaZaid1
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
LEFLOT Jean-Louis
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
Dr.pavithra Anandan
 
DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
anaghabharat01
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
suvadeepdas911
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
MedicoseAcademics
 
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptxOutbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
Pratik328635
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptxCLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
Government Dental College & Hospital Srinagar
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
Dr. Nikhilkumar Sakle
 

Recently uploaded (20)

MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHYMERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
 
How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
 
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
 
DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
 
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptxOutbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptxCLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
 

Greg Warren

  • 1. Treatment and Recovery in America April 10-12, 2012 Walt Disney World Swan Resort
  • 2. Accepted Learning Objectives: 1. Define when and how medication-assisted treatment methodologies for successful recovery of opioid addiction should be used. 2. Explain how to improve access and quality of care through strategic planning and community-wide coordination with local and state agencies. 3. Describe behavioral health issues faced by individuals within the corrections system and devise strategies to adequately address these clinical needs after incarceration.
  • 3. Disclosure Statement •  All presenters for this session, Dr. Elinore McCance-Katz and Gregory C. Warren, have disclosed no relevant, real or apparent personal or professional financial relationships.
  • 4. Baltimore Substance Abuse Systems, Inc. Nuts and Bolts of Medication Assisted Treatment and System Coordination
  • 5. Baltimore Substance Abuse Systems, Inc. BSAS is a quasi-public agency incorporated in 1990. In 1995, BSAS became responsible for the management of the publicly-funded substance abuse treatment and prevention service system. The Chair of the 27-member Board is the Commissioner of Health.
  • 6. Baltimore City’s Challenge •  Heroin addiction remains high –  Treatment capacity falls short of demand despite expansion in treatment system –  Estimated 30,000 individuals with opioid dependence –  ~4,000 methadone treatment slots –  Over 8,000 treatment admissions for opioids in FY 2008 •  Consequences from heroin addiction are severe –  Crime –  Family and community disruption –  Medical complications •  1 in 48 Baltimore City residents are living with HIV and/or AIDS
  • 7. , . 57% arrested 71% Unemployed in the 50% < $10,000 per yr. past 2 years Characteristics of Clients in 60% Baltimore City Programs 13% male Homeless FY 2010 77% use Treatment tobacco 45% Episodes less than a 12th n = 21,000 grade education 70% between 83% Black, 30-50 years 16% White of age Less than 1% Hispanic
  • 8. Neighborhood Factors •  78% felt drugs was a major problem •  31% felt neighborhood was safe to live •  26% felt neighborhood was a good place to find a job •  59% felt living in the neighborhood made it hard to stay out of jail
  • 9.
  • 10. BSAS Vision and Mission VISION We envision Baltimore as a city with healthy people, thriving families and safe communities. Mission Baltimore Substance Abuse Systems seeks to ensure that Baltimore residents receive high quality and comprehensive services proved to prevent and reduce substance abuse. HOW WE WILL ACHIEVE THIS We do this by planning, advocating for and helping to create coordinated networks of community-based and recovery focused services that build on the strengths and resilience of individuals, families, and communities.
  • 11. Concerns for the Future •  Do our citizens have access to care? •  Do our citizens receive quality care? •  Individualized, continuous, coordinated care is better than disjointed, acute care which ignores the importance of the family and community •  Cultural and clinical diversity of services are better than “cookie cutter treatment”
  • 12. Key Philosophical Understandings •  Pain and suffering are powerful motivators for change •  We need to be where people have their motivational moments •  Medication assisted treatment provides the time for counseling to work
  • 13. Recovery Oriented Systems of Care (ROSC) Networks of formal and informal services developed and mobilized to sustain long- term recovery for individuals and families impacted by substance abuse. “ The act of asking what the patient wants instead of what will be done to the patient.”
  • 14. Buprenorphine: 14 Methadone: 13
  • 15. What is different about buprenorphine?
  • 16. Buprenorphine Formulations Buprenex (for pain only) Subutex (for opioid addiction only) Suboxone (for opioid addiction only, with naloxone)
  • 17. How long do people need to stay on buprenorphine? •  Individualized •  Studies demonstrate that staying on medication in combination with counseling results in much better outcomes than detox •  50% relapse rate within a year among patients who came off
  • 18. Outcomes for Treatment As Usual •  Of 3,753 admissions to Level I treatment in FY08, 51% retained for 90 days or more •  Of 11,013 treatment discharges in FY08, only Prince George’s county had smaller change in substance use •  Relapse rates high –  In methadone studies, 50-80% relapse within one year after detoxification –  91% of patients receiving buprenorphine for 4 months had relapsed to prescription opioids within 2 months of taper*
  • 19. Business Case for BBI in 2006 •  Baltimore needs more effective treatment for opioid dependence •  Review of literature and studies by UMBC –  Medical costs are increased for patients with drug abuse –  Opioid addicts on methadone consume far fewer Medicaid resources than addicts who go untreated –  Buprenorphine is economically viable alternative in city with limited methadone treatment capacity 19
  • 20. Dept of Public Safety and Correctional Services •  Maryland manages the Detention Center –  4,000 inmates •  Men have a LOS of 28 days •  Women have a LOS of 60 days •  Division of Correction –  22,000 inmate population •  12,000 released annually •  9,000 are Baltimore City residents –  Over 70% have a diagnosis of Substance Abuse
  • 21. OTP Interventions •  Maintain arrested OTP clients during Pre-Trial Status and reconnect them to their OTP at release •  Detox heroin-addicted inmates with non-opioids or on methadone •  Pregnancy protocol •  Buprenorphine conversion
  • 22. Criminal History of Prison-based OTP Patients 1 Mean Age first crime 13.8 Age first arrest 16.5 Age first incarceration 20.6 Lifetime incarcerations 9.1 Past 30 days crime 25.5 Past 30 days crime-profit 24.8 Criminal Income ($/past 8,057 30 days) 1 Kinlock, Schwartz Gordon (2005)
  • 23. Treating Prisoners with Heroin Addiction Histories   Most detainees with histories of heroin addiction do not receive drug abuse treatment while incarcerated   Such inmates typically become re-addicted within one month of release   Re-addiction is accompanied by the following:   Increased criminal activity   Unemployment   High risk of HIV infection   Greater risk of overdose death   Incarceration
  • 24. Offenders have more serious Substance Use & Other Disorders •  Offenders Have Higher Rates of Psycho-Social Dysfunctional Than the General Population –  Substance Use Disorders –  Mental Health and Somatic Health Disorders –  Educational Deficiencies •  CJ Populations: 4 Times Greater SA Disorders NSDUH  2007  
  • 25. BBI Results 3,209 patients • Currently, 357 treated patients receiving full BBI services in 2,094 (65%) obtained or had medical assistance treatment program 1,645 (79%) 449 (21%) PAC Health Choice • Approximately 6% drop-out from 796 (38%) continuing care transferred to continuing care
  • 26. bSAS and B-MAT: Results •  After controlling for baseline group differences, the B-MAT group had less: –  Inpatient hospital admissions –  Inpatient days in hospital –  Outpatient hospital visits –  Emergency room visits –  Physician visits •  However, the only statistically significant differences compared to M-MAT and Abstinence-based treatment was for physician visits •  The M-MAT group has more health problems while the B-MAT and Abstinence groups have similar profiles 26
  • 27. Factors to Improve Networkness? Integration or Boundaryless Processes of SA & CJ Agencies Most Typical Activities: •  Share Information with   Average Number of agencies Activities Integrated: •  Develop Client Eligibility   Drug Court=6.1 Across Agencies   Probation/Parole=4.5 •  Written Program   Prison=3.2 Programs   Jails=3.7 •  Joint Staffing of Program   Interagency integration is •  Modified Program to Meet associated with more use Correctional and SA of EBPs, more holistic Agencies services, and improved outcomes •  Written MOU between agency Fletcher,  et  al,  in  press  ;  Taxman  &  Perdoni,  2007  
  • 28. Project ACCESS •  Accountability •  Communication •  Collaboration •  Efficiency •  Security of Information •  Service focus
  • 29. BSAS ACCESS Supports BSAS, Vision, Mission and Goals   EHRc Information Sharing supports continuity of care.  EHRc Information Sharing furthers the goals of a ROSC approach.  EHRc Information Sharing frees up funding and staff so that it can be applied to improved Quality of Care. • EHRc Information Sharing expands, consolidates and improves the quality of Public Health Data Repository. • EHRc Information Sharing provides better quality and more complete data for evaluation and outcome reporting.
  • 30. BSAS ACCESS Health Information Strategic Planning   New ways to collect, share and use data to serve client.   Interoperable systems and smooth information flow.   “Wherever you go, there you are” •  Better Quality data – reliable, consistent, complete. •  New partnerships and collaborations in evaluating and applying meaningful data. •  Confidentiality and Consent
  • 31. What providers tell us they want from their Information Systems (From focus group discussions, interviews and in depth needs analyses)   A fully functional, modern and meaningful use certified EHR   Consolidation of Information Systems and elimination of redundant applications   Access to additional client data and interoperability with other client data systems •  Pricing discounts and additional leverage associated with forming an EHR (HIT) consortium •  Business practice and clinical practice management Information Systems improvements •  HIT advisement – How to get CMS incentive payments and how to avoid penalties
  • 32. Draft - ACCESS Advisory Board •  Behavioral Health Treatment Providers (2) •  Consumers (2) •  BSAS CEO •  BSAS CIO •  DPSCS CIO •  Baltimore City CIO •  DHMH CIO •  BSAS Epidemiologist •  University of Maryland Law Clinic •  Health Care Access Maryland
  • 33. Treatment Outcomes for the Criminal Justice Population Criminal Justice Populations Drug Treatment Court Other Criminal Justice N = 1,353 N = 2,745 Completion: 1,068 Completion: 1,687 Incarceration: 21 Incarceration: 71 Terminated: 264 Terminated: 987 Treatment Outcomes Drug Court Non-Drug Court Drug use during treatment 13% 38% Substance use at discharge 10% 25% 90 day retention in outpatient treatment (Level I) 63% 57% Completion of outpatient treatment (Level I) 52% 34% Continuity of care from ICF (Level III.7) to another LOC 73% 35% % change in employment from admission to discharge 183% 52%
  • 34. Treatment Outcomes for the Criminal Justice Population Criminal Justice Populations Drug Treatment Court Other Criminal Justice N = 1,353 N = 2,745 Completion: 1,068 Completion: 1,687 Incarceration: 21 Incarceration: 71 Terminated: 264 Terminated: 987 Treatment Outcomes Drug Court Non-Drug Court Drug use during treatment 13% 38% Substance use at discharge 10% 25% 90 day retention in outpatient treatment (Level I) 63% 57% Completion of outpatient treatment (Level I) 52% 34% Continuity of care from ICF (Level III.7) to another LOC 73% 35% % change in employment from admission to discharge 183% 52%
  • 35. Access: The Patient-Centered, Clinical Case Management Approach A Recovery Oriented System of Care Not Constrained by Walls Offender Patient NEEDS NEEDS • Custody • Substance Abuse treatment • Somatic Care • Mental Health treatment • Substance Abuse Treatment • Somatic Care • Mental Health Treatment • Housing • Case Management • Entitlement Benefits • Family Support Services • Faith-Based Services DPDS DOC DPP Health Dept./Community Services
  • 36. Shared Critical Understanding •  Correctional Services is an expectation of the public •  DPSCS is a part of Maryland’s public health system •  Our success is measured long after our offenders/patients leave
  • 37. DPSCS and BSAS have a Shared Challenge Information must follow the offender/ patient and not reside and remain at the institution for it to do the greatest good. The Patient-Centered Approach
  • 38. The Benefits of a DPSCS/BSAS Partnership •  BSAS will champion critical value added linkages which will improve offender’s health outcomes •  DPSCS/BSAS health information exchange becomes a higher priority to CRISP •  Direct benefit to 9,000 returning Baltimore City offenders annually
  • 39. BSAS ACCESS The Value Proposition  Full-featured, meaningful use certified EHR for providers and partners.  Consolidation of multiple provider applications on a single operating platform. (Replace UP and eliminate SMART data entry.)  Information sharing between community resources and DPSCS.  Steep discounts for high quality solution to providers and partners. •  More efficient and cost effective clinical and practice management for providers and partners • BSAS consultation and assistance in securing Medicaid incentive payments. • Information sharing between BSAS provider network, mental health, primary care providers, and other community resources. • Primary source, comprehensive public health data repository. • Comprehensive statistical evaluation and outcome reporting
  • 40. BSAS- ACCESS Design & Implementation •  Secure, segregated installations on a common operating platform •  Custom module selection and configuration. •  Economies of scale and cost reductions •  Data sharing and information exchange •  Aggregate public health data
  • 41. BSAS ACCESS Patient Management Work Flow Intake Administration Client Referral / Client Scheduling and Releases Walk-in AND Consent DATA FROM OTHER CONSORTIUM MEMBERS Methadone (Other Meds) Clinical Case EPrescription Management / Management / Dispensing Documentation Billing /Accounts Standard Practice Compliance Reporting Receivable/Financial Management Management Reporting City, State, Federal
  • 42. BSAS Health Information Exchange DPSCS OCMS BSAS BSAS Methadon Residential e Programs BSAS BHCA Outpatien Entitlemen BSAS ACCESS t t Programs Benefits FQHC DHMH GE SMART Centricity Health Health Providers Departme thru CRISP nt